Clinical Trials in San Antonio

Showing 4901-4920 of 14,633 trials

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

NCT01127178

The purpose of this study is to determine the maximum tolerated dose (MTD) of poly (ADP-Ribose) polymerase inhibitor E7016 when used with temozolomide (TMZ) in patients with advanced solid tumors and gliomas.

Solid Tumors

Eisai Inc.12 participantsStarted Mar 2010

Boston, Massachusetts, United States • Lebanon, New Hampshire, United States • Greenville, South Carolina, United States +2 more locations

COMPLETEDPhase 1/2< 1 mile

Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder

NCT05132699

The primary goal of this pilot project is to demonstrate the safety and feasibility of using Cannabidiol (CBD) in combination with standard of care prolonged exposure (PE) psychotherapy to reduce PTSD symptoms.

Posttraumatic Stress DisorderStress Disorders, Post-Traumatic

The University of Texas Health Science Center at San Antonio21 participantsStarted Apr 2022

San Antonio, Texas, United States

COMPLETEDPhase 3< 1 mile

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

NCT04773587

This is a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) cream vs vehicle applied once daily (qd) for 4 weeks by participants with atopic dermatitis (eczema).

Atopic Dermatitis Eczema

Arcutis Biotherapeutics, Inc.654 participantsStarted Jan 2021

Montgomery, Alabama, United States • Scottsdale, Arizona, United States • Little Rock, Arkansas, United States +46 more locations

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Find Trials by Condition in San Antonio

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Observational Study of Obstructive Lung Disease (NOVELTY)

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study

Wearable Assessments in the Clinic and Home in PD

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission